EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c
May 12, 2015 7:00 AM EDT
BOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the first quarter ended March 31, 2015.
"We started the year off by raising close to $53 million from our public offering, enabling us to strengthen our balance sheet and add new long-term shareholders," stated Amit Munshi, President and Chief Executive Officer, EPIRUS... More
May 12, 2015 7:00 AM EDT
BOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced financial results for the first quarter ended March 31, 2015.
"We started the year off by raising close to $53 million from our public offering, enabling us to strengthen our balance sheet and add new long-term shareholders," stated Amit Munshi, President and Chief Executive Officer, EPIRUS... More
